SCHEMBL4772410

SCHEMBL4772410

O=C(NCCO)c1ccc(NS(=O)(=O)CCc2ccccc2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.53
NAMPT P43490 1/20 0.49
TRPV1 Q8NER1 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
PTGES2 Q9H7Z7 1/20 0.46
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 1/20 0.44
KMT2A Q03164 1/20 0.44
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43
CNR1 P21554 1/20 0.43
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777299 0.91 L3MBTL1 (0.46) HIF1AL3MBTL1NAMPTTRPV1SMN1; SMN2
SCHEMBL4777693 0.90 HIF1A (0.54) HIF1AL3MBTL1NAMPTTRPV1SMN1; SMN2
SCHEMBL4770958 0.88 HIF1A (0.52) HIF1AL3MBTL1NAMPTTRPV1SMN1; SMN2
SCHEMBL4776613 0.87 HIF1A (0.50) HIF1AL3MBTL1NAMPTTRPV1SMN1; SMN2
SCHEMBL4773260 0.84 L3MBTL1 (0.44) HIF1AL3MBTL1NAMPTTRPV1POLB
SCHEMBL4768066 0.84 PTGES2 (0.49) HIF1AL3MBTL1NAMPTTRPV1SMN1; SMN2
SCHEMBL4778580 0.82 SMN1; SMN2 (0.44) HIF1AL3MBTL1TRPV1SMN1; SMN2HPGD
SCHEMBL4771196 0.81 SMN1; SMN2 (0.53) HIF1AL3MBTL1NAMPTTRPV1SMN1; SMN2
SCHEMBL4777284 0.81 ACLY (0.49) HIF1AL3MBTL1NAMPTTRPV1SMN1; SMN2
SCHEMBL4774773 0.81 L3MBTL1 (0.46) HIF1AL3MBTL1NAMPTTRPV1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 HIF1A 4386/4885L3MBTL1 2781/4885NAMPT 3369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.